Cancer Immunotherapy Platform For Hypoxic Tumors

Mabpro is focused on developing a cancer immunotherapy platform specifically targeting aggressive, hypoxic tumors through the use of Carbonic Anhydrase IX (CA IX). This innovative approach is supported by extensive scientific literature and pre-clinical research, which indicate that targeting hypoxic tumors with CA IX can yield effective immunotherapies for both solid and lymphatic tumors. The company has identified five initial indications that account for a significant portion of cancer-related mortality and has developed two humanized monoclonal antibodies aimed at different cancer use-cases. With most pre-clinical work completed, Mabpro is preparing to initiate Phase I clinical trials in late 2024.

In addition to its therapeutic developments, Mabpro is also advancing companion diagnostics and patient stratification protocols to enhance treatment efficacy. The company holds a comprehensive intellectual property portfolio related to CA IX-based therapies, including proprietary rights and an exclusive license from the Slovak Academy of Sciences. Furthermore, Mabpro is exploring the potential applications of its technology beyond oncology, with initial investigations into cardiovascular diseases. This multifaceted approach positions Mabpro as a promising player in the biopharmaceutical landscape, particularly in the realm of personalized cancer treatment.

Slovakia

Personalized cancer immunotherapy for aggressive hypoxic tumors with blockbuster potential.

Our Target Mechanism For Treating Hypoxic Tumors: Carbonic Anhydrase IX (CA IX).

Our Mission:
- to fill the gap in treatment of oncology diseases with poor prognosis,
- to increase survival rate and bring hope to patients who have undergone different types of therapies without success,
- to deliver novel therapeutics that match the principle of personalized medicine which will help patients to improve the quality of their lives.

Crunchbase
https://www.crunchbase.com/organization/mabpro-therapeutics

Mabpro

Company Details